Targeting JNK1/2 and P38 Mitogen-Activated Protein Kinases With Pazopanib Mitigates Bleomycin-Induced Lung Fibrosis

IF 3.6 3区 医学 Q2 CHEMISTRY, MEDICINAL
Rasha Abdelhady, Rabab H. Sayed, Nancy S. Younis, Omaima Ali, Mai Abdallah Elhemely, Ahmed M. Ashour, Shuruq E. Alsufyani, Hany H. Arab, Mohammed S. Abdel-Hamid
{"title":"Targeting JNK1/2 and P38 Mitogen-Activated Protein Kinases With Pazopanib Mitigates Bleomycin-Induced Lung Fibrosis","authors":"Rasha Abdelhady,&nbsp;Rabab H. Sayed,&nbsp;Nancy S. Younis,&nbsp;Omaima Ali,&nbsp;Mai Abdallah Elhemely,&nbsp;Ahmed M. Ashour,&nbsp;Shuruq E. Alsufyani,&nbsp;Hany H. Arab,&nbsp;Mohammed S. Abdel-Hamid","doi":"10.1002/ardp.70105","DOIUrl":null,"url":null,"abstract":"<p>Idiopathic pulmonary fibrosis is considered the most common type of interstitial lung disease. The principal aim of our research was to investigate the potential role of pazopanib treatment in alleviating bleomycin-elicited pulmonary fibrosis and elucidate the underlying molecular mechanisms. Twenty-four male mice were allocated into four groups (<i>n</i> = 6): control animals (received saline intraperitoneally (i.p.)), bleomycin group received bleomycin (40 U/kg, i.p.) on 5 days, 0, 3, 7, 10, and 14, and bleomycin and pazopanib-treated group received bleomycin on the specified days and then received pazopanib (10 mg/kg, i.p.) once daily starting on Day 15 to Day 28, plus pazopanib-treated group, which received pazopanib only in the previously specified dose and duration. Our results demonstrated the promising role of pazopanib in mitigating pulmonary fibrosis, as reflected by the remarkable improvement in body weight loss and pulmonary histopathological features. This finding was primarily ascribed to the documented suppression of mitogen-activated protein kinase kinase kinase 2 (MEKK2) and MEKK3 mRNA expressions, which subsequently repressed p-c-Jun N-terminal kinase (p-JNK1/2) and p-P38 group of protein kinases (p-P38) protein expressions. Moreover, pazopanib administration to bleomycin-treated mice remarkably adjusted the bleomycin-mediated dysregulation of the levels of examined cytokines, including interleukin (IL)-1β, IL-13, IL-33, tumor necrosis factor-alpha (TNF-α), and nuclear factor kappa-B (NF-κB) P65. Remarkably, pazopanib treatment reversed the bleomycin-induced elevation in transforming growth factor-beta-1 (TGF-β1) and α-smooth muscle actin (α-SMA) levels. Our research highlighted the beneficial role of pazopanib in attenuating bleomycin-elicited lung fibrosis through the suppression of MEKK2 and MEKK3 and the modulation of JNK and P38 cascades.</p>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"358 9","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2025-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477462/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archiv der Pharmazie","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ardp.70105","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Idiopathic pulmonary fibrosis is considered the most common type of interstitial lung disease. The principal aim of our research was to investigate the potential role of pazopanib treatment in alleviating bleomycin-elicited pulmonary fibrosis and elucidate the underlying molecular mechanisms. Twenty-four male mice were allocated into four groups (n = 6): control animals (received saline intraperitoneally (i.p.)), bleomycin group received bleomycin (40 U/kg, i.p.) on 5 days, 0, 3, 7, 10, and 14, and bleomycin and pazopanib-treated group received bleomycin on the specified days and then received pazopanib (10 mg/kg, i.p.) once daily starting on Day 15 to Day 28, plus pazopanib-treated group, which received pazopanib only in the previously specified dose and duration. Our results demonstrated the promising role of pazopanib in mitigating pulmonary fibrosis, as reflected by the remarkable improvement in body weight loss and pulmonary histopathological features. This finding was primarily ascribed to the documented suppression of mitogen-activated protein kinase kinase kinase 2 (MEKK2) and MEKK3 mRNA expressions, which subsequently repressed p-c-Jun N-terminal kinase (p-JNK1/2) and p-P38 group of protein kinases (p-P38) protein expressions. Moreover, pazopanib administration to bleomycin-treated mice remarkably adjusted the bleomycin-mediated dysregulation of the levels of examined cytokines, including interleukin (IL)-1β, IL-13, IL-33, tumor necrosis factor-alpha (TNF-α), and nuclear factor kappa-B (NF-κB) P65. Remarkably, pazopanib treatment reversed the bleomycin-induced elevation in transforming growth factor-beta-1 (TGF-β1) and α-smooth muscle actin (α-SMA) levels. Our research highlighted the beneficial role of pazopanib in attenuating bleomycin-elicited lung fibrosis through the suppression of MEKK2 and MEKK3 and the modulation of JNK and P38 cascades.

帕唑帕尼靶向JNK1/2和P38丝裂原活化蛋白激酶减轻博莱霉素诱导的肺纤维化。
特发性肺纤维化被认为是肺间质性疾病最常见的类型。我们研究的主要目的是研究帕唑帕尼治疗在缓解博莱霉素引起的肺纤维化中的潜在作用,并阐明其潜在的分子机制。将24只雄性小鼠分为4组(n = 6):对照动物(腹腔注射生理盐水),博来霉素组在第5天、第0天、第3天、第7天、第10天、第14天注射博来霉素(40 U/kg,每日1次),博来霉素和帕唑帕尼治疗组在第15天至第28天开始注射博来霉素,然后再注射帕唑帕尼(10 mg/kg,每日1次),帕唑帕尼治疗组只按先前规定的剂量和持续时间注射帕唑帕尼。我们的研究结果表明,帕唑帕尼在减轻肺纤维化方面有希望的作用,这反映在体重减轻和肺组织病理学特征的显着改善上。这一发现主要归因于有记录的丝裂原活化蛋白激酶激酶2 (MEKK2)和MEKK3 mRNA表达的抑制,这随后抑制了p-c-Jun n末端激酶(p-JNK1/2)和p-P38蛋白激酶(p-P38)蛋白的表达。此外,pazopanib给药博来霉素处理的小鼠显著调节了博来霉素介导的检测细胞因子水平的失调,包括白细胞介素(IL)-1β、IL-13、IL-33、肿瘤坏死因子α (TNF-α)和核因子κ b (NF-κB) P65。值得注意的是,帕唑帕尼治疗逆转了博莱霉素诱导的转化生长因子-β -1 (TGF-β1)和α-平滑肌肌动蛋白(α-SMA)水平升高。我们的研究强调了pazopanib通过抑制MEKK2和MEKK3以及调节JNK和P38级联来减轻博莱霉素引起的肺纤维化的有益作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Archiv der Pharmazie
Archiv der Pharmazie 医学-化学综合
CiteScore
7.90
自引率
5.90%
发文量
176
审稿时长
3.0 months
期刊介绍: Archiv der Pharmazie - Chemistry in Life Sciences is an international journal devoted to research and development in all fields of pharmaceutical and medicinal chemistry. Emphasis is put on papers combining synthetic organic chemistry, structural biology, molecular modelling, bioorganic chemistry, natural products chemistry, biochemistry or analytical methods with pharmaceutical or medicinal aspects such as biological activity. The focus of this journal is put on original research papers, but other scientifically valuable contributions (e.g. reviews, minireviews, highlights, symposia contributions, discussions, and essays) are also welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信